The effect of NSC-631570 (Ukrain) alone and in combination with pathogen-associated molecules on cell cycle distribution and apoptosis induction of mouse melanoma cells with different biological properties

Experimental Oncology

Volumn 32, Issue 2, 2010, Pages 92-96

  Skivka, L M ^a   Trompak, O O ^b   Kudryavets, Yu I ^c   Bezdenezhnykh, N A ^c   Susak, Ya M ^d  

^a TARAS SHEVCHENKO NATIONAL UNIVERSITY OF KYIV   (Ukraine)

^b NATIONAL UNIVERSITY OF KYIV MOHYLA ACADEMY   (Ukraine)

^c R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^d BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

Author keywords

Antitumor drug NSC 631570 (Ukrain); Melanoma cell lines; Metastatic capabilities; TAP genes

Indexed keywords

NATURAL PRODUCT; NSC 631570; PATHOGEN ASSOCIATED MOLECULE; TRYPAN BLUE; UKRAIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DIVISION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DNA GEL ELECTROPHORESIS; DRUG EFFECT; FLOW CYTOMETRY; GEL ELECTROPHORESIS; GENE; GENE EXPRESSION; GROWTH RATE; IN VITRO STUDY; MELANOMA; MELANOMA CELL; METAPHASE; METASTASIS; MITOSIS; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TAP GENE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BERBERINE ALKALOIDS; CELL CYCLE; CELL LINE, TUMOR; CELL SEPARATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; MELANOMA; MICE; MICE, INBRED C57BL; PHENANTHRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAPHYLOCOCCUS AUREUS;

EID: 77954609488     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Tucker MA. Melanoma epidemiology. Hematol Oncol Clin North Am 2009; 23: 383-95.
2. Verma S, Quirt I, McCready D, et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106: 1431-42.
3. Postovit LM, Margaryan NV, Seftor EA, et al. Role of nodal signaling and the microenvironment underlying melanoma plasticity. Pigment Cell Melanoma Res 2008; 21: 348-57.
4. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445: 851-7. (Pubitemid 46309849)
5. Johansson M, Persson JL. Cancer therapy: targeting cell cycle regulators. Anticancer Agents Med Chem 2008; 8: 723-31.
6. Doroshenko YM, Karavay AV, Hodysh YY, et al. The dynamics of concentration of the main fluorescent component of Ukrain in the tissues and blood plasma of rats with W-256 tumor after a single intravenous injection. Drugs Exp Clin Res 2000; 26: 171-7.
7. Lanvers-Kaminsky C, Nolting DM, Koster J, et al. In vitro toxicity of Ukrain against human Ewing tumor cell lines. Anticancer Drugs 2006; 17: 1025-30.
8. Ernst E, Schmidt K. Ukrain - a new cancer cure? A systematic review of randomized clinical trials. BMC Cancer 2005; 5: 69. (Pubitemid 41461062)
9. Zemskov VS, Susak YM, Todor IN, et al. Antimetastat ic effect of Ukrain and its influence on the oxygen and energy metabolism in mice with melanoma B-16. Exp Oncol 1996; 18: 175-7.
10. Zemskov SV, Khranovska NN, Skachkova OV, et al. New dendritic cell based immunotherapy regime in treatment of metastatic melanoma. Ann Oncol 2008; 19: l30-2.
11. Stabuc B, Benedicic D. Ukrain with chemotherapy in malignant melanoma (case report). Drugs Exp Clin Res 1996; 22: 231-3. (Pubitemid 26336281)
12. Hamler F, Hiesmayr W, Korsh OB, et al. Ukrain monotherapy in malignant melanoma (case report). Drugs Exptl Clin Res 1996; XXII: 163-6.
13. Kemeny-Beke A, Aradi J, Damjanovich J, et al. Apoptotic response of uveal melanoma cells upon treatment with chelidonine, sanguinarine and chelerythrine. Cancer Lett 2006; 237: 67-75.
14. Ishii KJ, Uematsu S, Akira S. "Toll" gates for future immunotherapy. Curr Pharm Des 2006; 12: 4135-42.
15. Yu L, Chen S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother 2008; 57: 1271-8.
16. Salaun B, Lebecque S, Matikainen S, et al. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 2007; 13: 4565-74.
17. Farhat K, Riekenberg S, Heine H, et al. Heterodimerization of TLR2 with TLRl or TLR6 expands the ligand spectrum but does not lead to dilTerential signaling. J Leukoc Biol 2008; 83: 692-701.
18. Skivka LM, Fedorchuk OG, Susak YM, et al. The effect of NSC-631570 (Ukrain) on growth of low- and high-metastasing melanoma in mice. Pigment Cell Melanoma Res 2009; 22: 898-9.
19. Kudryavets YuI, Philchenkov AA, Abramenko IV, et al. Dynamics of apoptotic events induced in human leukemia U-937 cells by tumor necrosis factor. Exp Oncol 1996; 18: 353-65.
20. Kudryavets YuI. Interferon-alpha enhances development of apoptosis induced by various agents in tumor cells in vitro. Exp Oncol 2001; 23: 267-73.
21. Kudryavets YuI, Bezdenezhnykh NO, Lukyanova NYu, et al. Modifyin g influence of prolonged action of interferon on phenotypic characteristics of human lung cancer cells in vitro. Exp Oncol 2008; 30: 283-8.
22. Roublevskaia IN, Polevoda BV, Ludlow JW, et al. Induced G2/M arrest and apoptosis in human epidermoid carcinoma cell lines by semisynthetic drug Ukrain. Anticancer Res 2000; 20: 3163-7.
23. Kazmin SD, Todor IN. The effect of antitumor drug Ukrain on malignant proliferating cells being at different stages of cell cycle. Int J Biol Environ 2000; 28: 57-64.
24. Chen R, Alvero AB, Silasi DA, et al. Cancers take their Toll-the function and regulation of Toll-like receptors in cancer cells. Oncogene 2008; 27: 225-33.
25. Wolska A, Lech-Mararida E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett 2009; 14: 248-72.
26. Inglefield JR, Larson CJ, Gibson SJ, et al. Apoptotic responses in squamous carcinoma and epithelial cells to small-molecule toll-like receptor agonists evaluated with automated cytometry. J Biomol Screen 2006; 11: 575-85.